Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caris Life Sciences (CAI) Gross Profit (2024 - 2025)

Caris Life Sciences has reported Gross Profit over the past 2 years, most recently at $248.7 million for Q4 2025.

  • Quarterly results put Gross Profit at $248.7 million for Q4 2025, up 169.22% from a year ago — trailing twelve months through Dec 2025 was $655.8 million (changed N/A YoY), and the annual figure for FY2025 was $644.5 million, up 148.22%.
  • Gross Profit for Q4 2025 was $248.7 million at Caris Life Sciences, up from $175.6 million in the prior quarter.
  • Over the last five years, Gross Profit for CAI hit a ceiling of $248.7 million in Q4 2025 and a floor of $61.3 million in Q2 2024.